Review Article
Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications
Table 1
Major published and ongoing clinical studies targeting inflammation therapies in coronary artery disease.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Footnote. ACS: acute coronary syndrome; CRP: C-reactive protein; CMR: cardiovascular magnetic resonance; LoDoCo: Low-Dose Colchicine; CANTOS: Canakinumab. Anti-Inflammatory Thrombosis Outcome Study; CIRT: Cardiovascular Inflammation Reduction Trial; COLCOT: Colchicine Cardiovascular Outcomes Trial; CLEAR-SYNERGY: Colchicine and Spironolactone in Patients with STEMI/SYNERGY Stent Registry; LoDoCo2: Low Dose Colchicine After Myocardial Infarction; ASSAIL-MI: ASSessing the Effect of Anti-IL-6 Treatment in MI; LATITUDE-TIMI 60: LosmApimod To InhibiT p38 MAP kinase as a therapeUtic target and moDify outcomes after an acute coronary syndrome; VCU-ART3: Virginia Commonwealth University-Anakinra Remodeling Trial-3. |